|
Status |
Public on May 30, 2012 |
Title |
Mouse number 1981 |
Sample type |
genomic |
|
|
Channel 1 |
Source name |
Lfng conditional mutant non-tumor gDNA
|
Organism |
Mus musculus |
Characteristics |
strain: FVB identifier: Mouse number 1981 reference type: non-tumor, control DNA
|
Extracted molecule |
genomic DNA |
Extraction protocol |
Genomic DNAs were purified using DNAeasy kits (Qiagen) combined with phenol-chloroform extraction.
|
Label |
Cy3
|
Label protocol |
The Invitrogen BioPrime CGH labeling kit was used (Cat#18094011) according to manufacturer's protocol
|
|
|
Channel 2 |
Source name |
Lfng conditional mutant mouse mammary tumor
|
Organism |
Mus musculus |
Characteristics |
identifier: Mouse number 1981 mammary tumor type: EMT/Spindle type tumor
|
Extracted molecule |
genomic DNA |
Extraction protocol |
Genomic DNAs were purified using DNAeasy kits (Qiagen) combined with phenol-chloroform extraction.
|
Label |
Cy5
|
Label protocol |
The Invitrogen BioPrime CGH labeling kit was used (Cat#18094011) according to manufacturer's protocol
|
|
|
|
Hybridization protocol |
2 ug of each DNA sample was hybridized according to the 40-hour manual protocol described by the manufacturer
|
Scan protocol |
The arrays were scanned at 5 micron resolution in an Agilent scanner
|
Description |
Tumor DNA is being compared to control DNA from the same animal M1M_081010R_SE2_1981_252741410150_S01_CGH_105_Jan09.txt
|
Data processing |
The images were processed with Agilent feature extraction version 9.5.1.1
|
|
|
Submission date |
Feb 16, 2012 |
Last update date |
May 30, 2012 |
Contact name |
Sean Eoin Egan |
E-mail(s) |
segan@sickkids.ca
|
Phone |
416-813-5267
|
Fax |
416-813-5252
|
Organization name |
The Hospital for Sick Children
|
Department |
Program in Developmental and Stem Cell Biology
|
Street address |
101 College Street, rm 14-309
|
City |
Toronto |
State/province |
Ontario |
ZIP/Postal code |
M5G 1L7 |
Country |
Canada |
|
|
Platform ID |
GPL10448 |
Series (1) |
GSE35855 |
Lunatic fringe deficiency cooperates with the Met/Caveolin amplicon to induce basal-like breast cancer |
|